-
1Academic Journal
Source: Zaporozhye мedical journal; Vol. 23 No. 1 (2021); 24-31 ; Запорожский медицинский журнал; Том 23 № 1 (2021); 24-31 ; Запорізький медичний журнал; Том 23 № 1 (2021); 24-31 ; 2310-1210 ; 2306-4145
Subject Terms: хроническая сердечная недостаточность с сохраненной фракцией выброса левого желудочка, пентоксифиллин, диастолическая дисфункция, качество жизни, пожилой возраст, chronic heart failure with preserved left ventricular ejection fraction, pentoxifylline, diastolic dysfunction, quality of life, aged, хронічна серцева недостатність зі збереженою фракцією викиду лівого шлуночка, пентоксифілін, діастолічна дисфункція, якість життя, похилий вік
File Description: application/pdf
Relation: http://zmj.zsmu.edu.ua/article/view/224839/225164; http://zmj.zsmu.edu.ua/article/view/224839
Availability: http://zmj.zsmu.edu.ua/article/view/224839
-
2Academic Journal
Authors: O. M. Zherko, E. I. Shkrebneva, О. М. Жерко, Э. И. Шкребнева
Source: Medical Visualization; Том 25, № 3 (2021); 83-96 ; Медицинская визуализация; Том 25, № 3 (2021); 83-96 ; 2408-9516 ; 1607-0763
Subject Terms: балльная шкала, 2D Speckle Tracking echocardiography, chronic heart failure with preserved ejection fraction, score scale, 2D Speckle Tracking эхокардиография, хроническая сердечная недостаточность с сохраненной фракцией выброса
File Description: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/939/674; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/969; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/970; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/971; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/972; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/973; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/974; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/975; Pieske B., Tschöpe C., de Boer R.A., Fraser A.G., Anker S.D., Donal E., Edelmann F., Fu M., Guazzi M., Lam C.S.P., Lancellotti P., Melenovsky V., Morris D.A., Nagel E., Pieske-Kraigher E., Ponikowski P., Solomon S.D., Vasan R.S., Rutten F.H., Voors A.A., Ruschitzka F., Paulus W.J., Seferovic P., Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFAPEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J. 2019; 40 (40): 3297–3317. http://doi.org/10.1093/eurheartj/ehz641.; Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., González-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M.C., Ruilope L.M., Ruschitzka F., Rutten F.H., van der Meer P.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37 (27): 21292200. https://doi.org/10.1093/eurheartj/ehw128; Lourenço A.P., Leite-Moreira A.F., Balligand J.L., Bauersachs J., Dawson D., de Boer R.A., de Windt L.J., Falcão-Pires I., Fontes-Carvalho R., Franz S., Giacca M., Hilfiker-Kleiner D., Hirsch E., Maack C., Mayr M., Pieske B., Thum T., Tocchetti C.G., Brutsaert D.L., Heymans S. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur. J. Heart Fail. 2018; 20 (2): 216–227. http://doi.org/10.1002/ejhf.1059; Сердечная недостаточность / Под общей ред. Ю.П. Островского. Минск: Беларуская навука, 2016. 503 с.; Patel A.R., Blair J.A. Heart Failure With Preserved Ejection Fraction Have We Finally Found the Perfect Noninvasive Biomarker? Circulation: Cardiovascular Imaging. 2016; 9: e005905. https://doi.org/10.1161/CIRCIMAGING.116.005905; Gupta D.K. Heart Failure With Preserved Ejection Fraction: An Opportunity for Reflection. J. Am. Heart Assoc. 2017; 6 (2): e005595. http://doi.org/10.1161/JAHA.117.005595; Tobushi T., Nakano M., Hosokawa K., Koga H., Yamada A. Improved Diastolic Function Is Associated With Higher Cardiac Output in Patients With Heart Failure Irrespective of Left Ventricular Ejection Fraction. J. Am. Heart Assoc. 2017; 6: e003389. http://doi.org/10.1161/JAHA.116.003389; Shah A.M., Claggett B., Sweitzer N.K., Shah S.J., Anand I.S., Liu L., Pitt B., Pfeffer M.A., Solomon S.D. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation. 2015; 132: 402–414.; Garbi M., Edvardsen T., Bax J., Petersen S.E., McDonagh T., Filippatos G., Lancellotti P. EACVI appropriateness criteria for the use of cardiovascular imaging in heart failure derived from European National Imaging Societies voting. Eur. Heart J. – Cardiovasc. Imaging. 2016; 17: 711–721. https://doi.org/10.1093/ehjci/jew081; Douglas P.S., Carabello B.A., Lang R.M., Lopez L., Pellikka P.A., Picard M.H., Thomas J.D., Varghese P., Wang T.Y., Weissman N.J., Wilgus R. 2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Transthoracic Echocardiography) and the American Society of Echocardiography. Circulation: Cardiovascular Imaging. 2019; 12: e000027. https://doi.org/10.1161/HCI.0000000000000027; Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflmmation. J. Am. Coll. Cardiol. 2013; 62: 263–271.; Жерко О.М. Клиническая трансторакальная эхокардиография. Минск: Альфакнига, 2016. 832 с.; Otto C. The practice of clinical echocardiography. 5nd ed. Philadelphia, Pennsylvania: Elsevier, 2017. 965 р.; Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F. 3rd, Dokainish H., Edvardsen T., Flachskampf F.A., Gillebert T.C., Klein A.L., Lancellotti P., Marino P., Oh J.K., Popescu B.A., Waggoner A.D. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiography. 2016; 29: 277–314. https://doi.org/10.1016/j.echo.2016.01.011; Galiè N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M.A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L., Trindade P.T., Zompatori M., Hoeper M.; ESC Scientific Document Group. 2015 ESC/ ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart J. 2016; 37: 67–119. https://doi.org/10.1093/eurheartj/ehv317; Reddy Y.N.V., Carter R.E., Obokata M., Redfield M.M., Borlaug B.A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018; 138: 861–870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646; Flachskampf F.A., Biering-Sørensen T., Solomon S.D., Duvernoy O., Bjerner T., Smiseth O.A. Cardiac Imaging to Evaluate Left Ventricular Diastolic Function. JACC: Cardiovascular Imaging. 2015; 8 (9): 1071–1093. https://doi.org/10.1016/j.jcmg.2015.07.004; Kasner M., Westermann D., Lopez B., Gaub R., Escher F., Kühl U., Schultheiss H.P., Tschöpe C. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J. Am. Coll. Cardiol. 2011; 57: 977–985. http://doi.org/10.1016/j.jacc.2010.10.024; Dokainish H., Nguyen J.S., Sengupta R., Pillai M., Alam M., Bobek J., Lakkis N. Do additional echocardiographic variables increase the accuracy of E/e’ for predicting left ventricular filing pressure in normal ejection fraction? An echocardiographic and invasive hemodynamic study. J. Am. Soc. Echocardiogr. 2010; 23: 156–161. http://doi.org/10.1016/j.echo.2009.11.015; Collier P.A., Phelan D., Klein A.A. Test in Context: Myocardial Strain Measured by Speckle-Tracking Echocardiography. J. Am. Coll. Cardiol. 2017; 69: 10431056. http://doi.org/10.1016/j.jacc.2016.12.012; Vecera J., Penicka M., Eriksen M., Russell K., Bartunek J., Vanderheyden M., Smiseth O.A. Wasted septal work in left ventricular dyssynchrony: a novel principle to predict response to cardiac resynchronization therapy. Eur. Heart J. – Cardiovasc. Imaging. 2016; 17: 624–632. http://doi.org/10.1093/ehjci/jew019; Čelutkienė J., Plymen C.M., Flachskampf F.A., de Boer R.A., Grapsa J., Manka R., Anderson L., Garbi M., Barberis V., Filardi P.P., Gargiulo P., Zamorano J.L., Lainscak M., Seferovic P., Ruschitzka F., Rosano G.M.C., Nihoyannopoulos P. Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. EJHF. 2018; 20: 1615–1633. http://doi.org/10.1002/ejhf.1330; https://medvis.vidar.ru/jour/article/view/939
-
3Academic Journal
Authors: E. V. Reznik, V. A. Lazarev, S. V. Borisovskay, G. N. Golukhov, Е. В. Резник, В. А. Лазарев, С. В. Борисовская, Г. Н. Голухов
Source: The Russian Archives of Internal Medicine; Том 11, № 6 (2021); 457-465 ; Архивъ внутренней медицины; Том 11, № 6 (2021); 457-465 ; 2411-6564 ; 2226-6704
Subject Terms: кардиоренальный синдром, amyloid cardiomyopathy, chronic heart failure with preserved ejection fraction, atrial fibrillation, left ventricular hypertrophy, chronic kidney disease, proteinuria, nephrotic syndrome, cardiorenal syndrome, амилоидная кардиомиопатия, хроническая сердечная недостаточность с сохраненной фракцией выброса левого желудочка, фибрилляция предсердий, гипертрофия левого желудочка, хроническая болезнь почек, протеинурия, нефротический синдром
File Description: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/1337/1071; https://www.medarhive.ru/jour/article/view/1337/1079; https://www.medarhive.ru/jour/article/view/1337/1083; Rysava R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019; 34(9): 1460-6. doi:10.1093/ndt/gfy291. PubMed PMID: 30299492.; Kristen AV, Perz JB, Schonland SO et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant. 2007; 26(12): 1313-9. doi:10.1016/j.healun.2007.09.014. PubMed PMID: 18096484.; Dubrey SW, Cha K, Anderson J et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998; 91(2): 141-57. doi:10.1093/qjmed/91.2.141. PubMed PMID: 9578896.; Karafiatova L, Pika T. Amyloid cardiomyopathy. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2017; 161(2): 117-27. doi:10.5507/bp.2017.001. PubMed PMID: 28145535.; Резник Е.В., Нгуен Т.Л., Степанова Е.А. и др. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020; 10(6): 430-457. https://doi.org/10.20514/2226-6704-2020-10-6-430-457; Лысенко () Л.В., Рамеев В.В., Моисеев С.В. и др. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клин фармакол тер. 2020; 29(1): 13-24; Резник Е.В., Степанова E.A., Нгуен Т. и др. Ретроспективный анализ поражения сердечно-сосудистой системы у пациентов системным амилоидозом. Кардиоваскулярная терапия и профилактика. 2021; 20(1): 2496. Reznik E.V., Stepanova E.A., Nguyen T. et al. Retrospective analysis of cardiovascular involvement in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021; 20(1): 2496. [In Russian]; Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016; 68(12): 1323-41. doi:10.1016/j.jacc.2016.06.053. PubMed PMID: 27634125.; Резник Е.В., Никитин И.Г. Кардиоренальный синдром у пациентов с сердечной недостаточностью как этап кардиоренального континуума (часть 2): прогностическое значение, профилактика и лечение. Архивъ внутренней медицины. 2019; 9(2): 93-106. doi:10.20514/2226-6704-2019-9-2-93-106; Резник Е.В., Никитин И.Г. Кардиоренальный синдром у пациентов с сердечной недостаточностью как этап кардиоренального континуума (часть I): определение, классификация, патогенез, диагностика, эпидемиология (обзор литературы). Архивъ внутренней медицины. 2019; 9(1): 5-22. doi:10.20514/2226-6704-2019-9-1-5-22; Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. British journal of haematology. 2015; 168(2): 186-206. doi:10.1111/bjh.13155. PubMed PMID: 25303672.; Kastritis E, Dimopoulos MA. Recent advances in the management of AL Amyloidosis. British journal of haematology. 2016; 172(2): 170-86. doi:10.1111/bjh.13805. PubMed PMID: 26491974.; Fajardo J, Cummings A, Brown E et al. Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2019; 26(sup1): 166-7. doi:10.1080/13506129.2019.1583178. PubMed PMID: 31343333.; https://www.medarhive.ru/jour/article/view/1337
-
4Academic Journal
Authors: A. T. Teplyakov, A. V. Yakovlev, S. N. Shilov, N. F. Yakovleva, E. N. Berezikova, E. V. Grakova, K. V. Kopeva, S. D. Mayanskaya
Source: Бюллетень сибирской медицины, Vol 20, Iss 2, Pp 102-112 (2021)
Subject Terms: синдром обструктивного апноэ во сне, хроническая сердечная недостаточность с сохраненной фракцией выброса, правожелудочковая дисфункция, легочная гипертензия, Medicine
Relation: https://bulletin.ssmu.ru/jour/article/view/4386; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/3b81c85f6cf24bc580a0058a842b67e7
-
5Academic Journal
Authors: E. V. Reznik, T. L. Nguyen, E. A. Stepanova, D. V. Ustyuzhanin, I. G. Nikitin, Е. В. Резник, Т. Л. Нгуен, Е. А. Степанова, Д. В. Устюжанин, И. Г. Никитин
Contributors: The work was carried out within the framework of the state assignment of Russian National Research Medical University n.a. N.I. Pirogov, Ministry of Health of the Russian Federation (R&D state registration number AAAA-A18-118040390145-2), Работа выполнена в рамках государственного задания ФГАОУ ВО РНИМУ им. Н.И. Пирогова МЗ РФ (№ госрегистрации НИР АААА-А18-118040390145-2)
Source: The Russian Archives of Internal Medicine; Том 10, № 6 (2020); 430-457 ; Архивъ внутренней медицины; Том 10, № 6 (2020); 430-457 ; 2411-6564 ; 2226-6704
Subject Terms: нефротический синдром, amyloid cardiomyopathy, chronic heart failure with preserved ejection fraction, atrial fibrillation, left ventricular hypertrophy, chronic kidney disease, albuminuria, nephrotic syndrome, амилоидная кардиомиопатия, хроническая сердечная недостаточность с сохраненной фракцией выброса левого желудочка, фибрилляция предсердий, гипертрофия левого желудочка, хроническая болезнь почек, альбуминурия
File Description: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/1106/958; https://www.medarhive.ru/jour/article/view/1106/966; Hassan, W., et al., Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J, 2005. 32(2): p. 178-84.; Falk, R.H., et al., AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol, 2016. 68(12): p. 1323-41.; Mishra, S., et al., Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol, 2013. 305(1): p. H95-103.; Benson, M.D., et al., Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid, 2018. 25(4): p. 215-219.; Лысенко (Козловская), Л.В., В.В. Рамеев, and С.В. Моисеев, Клинические рекомендации по диагностике и лечению системного амилоидоза. Клиническая фармакология и терапия, 2020. 29(1): p. 13-24. DOI 10.32756/0869-5490-2020-1-13-24; Karafiatova, L. and T. Pika, Amyloid cardiomyopathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2017. 161(2): p. 117-127.; Fontana, M., et al., Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovasc Imaging, 2019. 12(11 Pt 2): p. 2345-2356.; Pinney, J.H., et al., Systemic amyloidosis in England: an epidemiological study. Br J Haematol, 2013. 161(4): p. 525-32.; Gilstrap, L.G., et al., Epidemiology of Cardiac AmyloidosisAssociated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail, 2019. 12(6): p. e005407.; Резник, Е.В., et al., Хроническая сердечная недостаточность у больных с системным амилоидозом. Кардиоваскулярная терапия и профилактика. in press.; Desport, E., et al., Al amyloidosis. Orphanet J Rare Dis, 2012. 7: p. 54.; Bird, J., et al., UK Myeloma Forum (U KMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation o f newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol, 2009. 147(1): p. 22-42.; Kastritis, E. and M.A. Dimopoulos, Recent advances in the management of AL Amyloidosis. Br J Haematol, 2016. 172(2) : p. 170-86.; Quarta, C.C., et al., The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med, 2015. 372(1): p. 21-9.; Maurer, M.S., et al., Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amy loidosis. Circ Heart Fail, 2019. 12(9): p. e006075.; Gillmore, J.D., et al., Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol, 2015. 168(2 ): p. 207-18.; Donnelly, J.P. and M. Hanna, Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med, 2017. 84( 12 Suppl 3): p. 12-26.; Hou, X., M.I. Aguilar, and D.H. Small, Transthyretin and familial amyloidotic polyneuropathy. Recent progress in un derstanding the molecular mechanism of neurodegeneration. FEBS J, 2007. 274(7): p. 1637-50.; Sekijima, Y., J.W. Kelly, and S. Ikeda, Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des, 2008. 14(30): p. 3219-30.; Gonzalez-Lopez, E., et al., Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J, 2015. 36(38): p. 2585-94.; Seferovic, P.M., et al., Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and p atient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail, 2019.; Damy, T., et al., Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J, 2016. 37(23): p. 1826-34.; Galat, A., et al., Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J, 2016 . 37(47): p. 3525-3531.; Castano, A., et al., Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with sev ere aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J, 2017. 38(38): p. 2879-2887.; Lopez-Sainz, A., et al., Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or co nduction disorders. Amyloid, 2019. 26(3): p. 156-163.; Гудкова, А.Я., Е.Н. Семернин, and А.А. Полякова, Спектр мутаций в гене транстиретина в когорте пациентов с хроничес кой сердечной недостаточностью. Трансляционная Медицина, 2016. 3(1): p. 34-38. https://doi.org/10.18705/2311-4495-2016-3-1-34-38.; Johnson, S.M., et al., The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol, 2012. 421(2-3): p. 185-203.; Ando, Y., et al., Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis, 2013. 8: p. 31.; Rapezzi, C., et al., Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively ca rdiac phenotype: an Italian perspective. Eur Heart J, 2013. 34(7): p. 520-8.; Sekijima, Y., et al., The current status of the Tran sthyretin Amyloidosis Outcomes Survey (THAOS) in Japan. Amyloid, 2019. 26(sup1): p. 61-62.; Damy, T., et al., Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyret in Amyloidosis Outcomes Survey (THAOS). Eur Heart J, 2019.; Plante-Bordeneuve, V., et al., The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin, 2013. 29(1): p. 77-84.; Coelho, T., M.S. Maurer, and O.B. Suhr, THAOS — The Transthyretin Amyloidosis Outcomes Survey: init ial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin, 2013. 29(1): p. 63-76.; Real de Asua , D., et al., Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol, 2014. 6: p. 369-77.; Leone, O., et al., Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J, 2004 . 25(14): p. 1237-41.; Rocken, C., et al., Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Ci rculation, 2002. 106(16): p. 2091-7.; Neben-Wittich, M.A., et al., Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primar y amyloidosis. Am J Med, 2005. 118(11): p. 1287.; Резник, Е.В., Г.Е. Гендлин, Г.И. Сторожаков, Эхокардиография в практике кардиолога. Москва, Пр актика; 2013. 212 с.; Fonta na, M., et al., Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev, 2015. 20(2): p. 133-44.; Kwong, R.Y., et al., Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function. Am J Cardiol, 2015. 116(4): p. 622-9.; Banypersad, S.M., et al., T1 mapping and survival in systemic lightchain amylo idosis. Eur Heart J, 2015. 36(4): p. 244-51.; Strouse, C., et al., Approach to a patient with cardiac amyloidosis. J Geriatr Cardiol, 2019. 16(7): p. 567-574.; Park, G.Y., et al., Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Dise ases. Int J Mol Sci, 2019. 20(12).; Caobelli, F., et al., Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR c ardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol, 2019.; Yamamoto, H. and T. Yok ochi, Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail, 2019. 6(6): p. 1128-1139.; Gopal, D.M., F. L. Ruberg, and O.K. Siddiqi, Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. Curr Heart Fail Rep, 2019. 16(5): p. 180-188.; Fajardo, J., et al., Clinical pat hway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. Amyloid, 2019. 26(sup1): p. 166-167.; Manolis, A.S., et al., Cardiac amyloidosis: An underdiagnosed/underappreciated disease. Eur J Intern Med, 2019. 67: p. 1-13.; Gertz, M.A., et al., Advances in the treatment of her editary transthyretin amyloidosis: A review. Brain Behav, 2019. 9(9): p. e01371.; Maurer, M.S., et al., Tafamidis Treatment for Patients with Transthyretin Amylo id Cardiomyopathy. N Engl J Med, 2018. 379(11): p. 1007-1016.; Wechalekar, A.D., et al., Guidelines on the management of AL am yloidosis. Br J Haematol, 2015. 168(2): p. 186-206.; Dember, L.M., et al., Eprodisate for the treatment of renal disease in AA amyloido sis. N Engl J Med, 2007. 356(23): p. 2349-60.; Zhu, H., J. Yu, and M.S. Kindy, Inhibition of amyloidosis using lowmolecular-weight heparins. Mol Med, 2001. 7(8): p. 517-22.; van der Hilst, J.C., et al., Lovastatin inhibits formation of AA amyloid. J Leukoc Biol, 2008. 83(5): p. 1295-9.; Gillmore, J.D., et al., Sustained pharmacological depletion of serum amyloid P component in patien ts with systemic amyloidosis. Br J Haematol, 2010. 148(5): p. 760-7.; Kluve-Beckerman, B., et al., Antisense oligonucleotide sup pression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid, 2011. 18(3): p. 136-46.; Kennel, S.J., et al., Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice. Amyloid, 2014. 21(1): p. 45-53.; Oerlemans, M., et al., Cardiac amyloidosis: the need for early diagnosis. Neth Heart J, 2019. 27(11): p. 525-536.; Sucker, C., et al., Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis, 2006. 47(6): p. 947-55.; Ishiguro, K., et al., Elevation of Plasmin-alpha2-plasmin Inhibitor Complex Predicts the Diagnos is of Systemic AL Amyloidosis in Patients with Monoclonal Protein. Intern Med, 2018. 57(6): p. 783-788.; https://www.medarhive.ru/jour/article/view/1106
-
6Academic Journal
Authors: Dushina A.G., Libis R.A.
Source: Almanac of Clinical Medicine; Vol 45, No 3 (2017); 247-253 ; Альманах клинической медицины; Vol 45, No 3 (2017); 247-253 ; 2587-9294 ; 2072-0505 ; 10.18786/2072-0505-2017-45-3
Subject Terms: late ventricular potentials, chronic heart failure with preserved ejection fraction, поздние потенциалы желудочков, хроническая сердечная недостаточность с сохраненной фракцией выброса
File Description: application/pdf
Relation: https://almclinmed.ru/jour/article/view/546/550; https://almclinmed.ru/jour/article/downloadSuppFile/546/1296; https://almclinmed.ru/jour/article/downloadSuppFile/546/1297; https://almclinmed.ru/jour/article/downloadSuppFile/546/1298; https://almclinmed.ru/jour/article/view/546
-
7Academic Journal
Authors: O. Drapkina M., L. Palatkina O., О. Драпкина М., Л. Палаткина О.
Source: Rational Pharmacotherapy in Cardiology; Vol 10, No 3 (2014); 317-321 ; Рациональная Фармакотерапия в Кардиологии; Vol 10, No 3 (2014); 317-321 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2014-10-3
Subject Terms: chronic heart failure, chronic heart failure with preserved ejection fraction, inflammation, cytokines, GDF-15, хроническая сердечная недостаточность, хроническая сердечная недостаточность с сохраненной фракцией выброса, воспаление, цитокины
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/258/269; Redfield M, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.; Drapkina OM, Ashihmin YaI, Ivashkin VT. Complexity of clinical diagnosis and treatment of diastolic congestive heart failure in patients with hypertension. Russian Medical News 2009; XIV (3): 3-17. Russian (Драпкина О.М., Ашихмин Я.И., Ивашкин В.Т. Сложности клинической диагностики и лече-ния диастолической хронической сердечной недостаточности у пациентов с артериальной ги-пертензией. Российские Медицинские Вести 2009; XIV(3): 3-17).; Agueyev FT. The modern concept of diastolic heart failure. Cardiovascular Therapy and Prevention 2010; 9 (7): 96-104. Russian (Агеев Ф.Т. Современная концепция диастолической сердечной недо-статочности. Кардиоваскулярная Терапия и Профилактика 2010; 9(7): 96- 104).; Owan T, Redfield M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005; 47: 320-32.; Agueyev FT, Danielian MO, Mareev VY, et al. Patients with chronic heart failure in the Russian outpatient practice: contingent features, diagnosis and treatment: a study of AGE-O-CHF. Heart Failure 2004; 5 (1): 4-7. Russian (Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и соавт. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения: исследование ЭПОХА-О-ХСН. Сердечная Недостаточность 2004; 5(1): 4-7).; Lee D, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119: 3070-7.; Mottaram P.M., Marwick T.H. Assessment of diastolic function: what the general cardiologist needs to know. Heart 2005; 91(5): 681-95.; Drapkina OM, Dubolazova YuV. "Portrait" diastolic heart failure. Arterial Hypertension 2010, 16 (6): 613-20. Russian (Драпкина, О.М., Дуболазова Ю.В. «Портрет» диастолической сердечной не-достаточности. Артериальная Гипертензия 2010;16(6): 613-20.; Agueyev FT. The evolution of ideas about the diastolic function. Heart Failure 2000; (2): 48-50. Russian (Агеев Ф.Т. Эволюция представлений о диастолической функции сердца. Сердечная недо-статочность 2000; (2): 48-50).; Wang J, Kurrelmeyer K, Torre-Amione G, et al. Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy. J Am Coll Cardiol 2007; 49: 88-96.; Mareev VY. Changing strategies for treating chronic heart failure. Time b-blockers. Cardiology 1998; (12): 4-11. Russian (Мареев В.Ю. Изменение стратегии лечения хронической сердечной не-достаточности. Время b-адреноблокаторов. Кардиология 1998; (12): 4-11).; van Heerebeek L, Franssen CP, Hamdani N, et.al. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep 2012;9(4):293-302.; Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004;94:1533-42.; Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358(20):2148-59.; Belenkov N., Agueyev FT, Mareev VY. Neurohormones and cytokines in heart failure: a new theory of the old disease. Heart Failure 2000; 1 (4) :135-8. Russian (Беленков Ю. Н., Агеев Ф. Т., Мареев В. Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого забо-левания. Сердечная Недостаточность 2000; 1(4):135-8).; Anker S, Egerer K, Volk H, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79: 1426-30.; Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New Engl J Med 1990; 323: 236-41.; Kapadia S, Dibbs Z, Kurrelmeyer K, et al. The role of cytokines in the failing human heart. Cardiol Clin 1998; 16: 645-56.; Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28: 964-71.; Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from of SOLVD. J Am Coll Cardiol 1996; 27: 1201-6.; Damas J, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res 2000; 45: 428-36.; Sharma R, Coats A, Anker S. The role of inflammatory mediators in chronic heart failure: cytokines, nitricoxide, andendothlin-1. Int J Cardiol 2000; 72: 175-86.; Berry C, Clark A. Catabolism in chronic heart failure. Eur Heart J 2000; 21: 521-32.; Gong K, Song G, Spiers J, et al. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. Int J Clin Pract 2007; 61: 611-21.; Clark D, Cleman M, Pfau S, et al. Serum complement activation in congestive heart failure. Am Heart J 2001; 14: 684-90.; Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62(4): 263-71.; Bradham W, Bozkurt B, Gunasinghe H, et al. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 2002; 53: 822-30.; Siwik D, Chang D, Colucci W. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86: 1259-65.; Sivasubramanian N, Coker M, Kurrelmeyer K, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001; 104: 826-31.; Peng J, Gurantz D, Tran V, et al. Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res 2002; 91: 1119-26.; Bootcov M. R., Bauskin A., Valenzuela S. M., et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-a superfamily cluster. Proc Natl Acad Sci USA 1997; 94: 11514-9.; Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1054-60.; Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010; 12: 1309-16.; Drapkina OM, Palatkina LO. Markers of cytokine activation and oxidative stress in patients with chronic heart failure. Heart Failure 2013; 14 (6): 341-6. Russian (Драпкина О. М., Палаткина Л. О. Мар-керы цитокиновой активации и оксидативного стресса у больных хронической сердечной не-достаточностью. Сердечная Недостаточность 2013; 14(6): 341-6).; Drapkina OM. RAAS and fibrosis. Hepato-cardiac relations. Russian Journal of Medicine 2011; 18: 1136-9. Russian (Драпкина О. М. РААС и фиброз. Гепатокардиальные связи. Русский Медицинский Журнал 2011; 18: 1136-9).; https://www.rpcardio.com/jour/article/view/258
-
8Academic Journal
Authors: O. M. Drapkina, L. O. Palatkina
Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 3, Pp 317-321 (2015)
Subject Terms: хроническая сердечная недостаточность, хроническая сердечная недостаточность с сохраненной фракцией выброса, воспаление, цитокины, GDF-15, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701
Relation: http://www.rpcardio.ru/jour/article/view/258; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653; https://doaj.org/article/81bca212ea0e4863a89b5b9615d18c58
-
9Academic Journal
Authors: Драпкина, Оксана, Палаткина, Людмила
Subject Terms: ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ С СОХРАНЕННОЙ ФРАКЦИЕЙ ВЫБРОСА, ВОСПАЛЕНИЕ, ЦИТОКИНЫ
File Description: text/html
-
10Academic Journal
Authors: Снеткова, А., Тимофеева, Н., Задионченко, В.
Subject Terms: ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ С СОХРАНЁННОЙ ФРАКЦИЕЙ ВЫБРОСА, ДИАСТОЛИЧЕСКАЯ ДИСФУНКЦИЯ, ЭНДОТЕЛИАЛЬНАЯ ДИСФУНКЦИЯ, ГАЛЕКТИН-3
File Description: text/html
-
11Academic Journal
-
12Academic Journal
Authors: Либис, Роман, Душина, Алена, Олейник, Елена
Subject Terms: ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ С СОХРАНЕННОЙ ФРАКЦИЕЙ ВЫБРОСА, ДИАСТОЛИЧЕСКАЯ ДИСФУНКЦИЯ, КАЧЕСТВО ЖИЗНИ
File Description: text/html
-
13Academic Journal
Source: Архивъ внутренней медицины.
Subject Terms: ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ С СОХРАНЁННОЙ ФРАКЦИЕЙ ВЫБРОСА, ПЕРИНДОПРИЛ, АМЛОДИПИН, 3. Good health
File Description: text/html
-
14Academic Journal
Source: Архивъ внутренней медицины.
Subject Terms: ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ С СОХРАНЁННОЙ ФРАКЦИЕЙ ВЫБРОСА, ДИАСТОЛИЧЕСКАЯ ДИСФУНКЦИЯ, ЭНДОТЕЛИАЛЬНАЯ ДИСФУНКЦИЯ, ГАЛЕКТИН-3, 3. Good health
File Description: text/html
-
15Academic Journal
Authors: Кохан Е.В., Киякбаев Г.К., Кобалава Ж.Д.
Source: Kardiologiia
Subject Terms: бета-адреноблокаторы, хроническая сердечная недостаточность с сохраненной фракцией выброса, частота сердечных сокращений, beta-blockers, chronic heart failure with preserved ejection fraction, heart rate
Availability: https://repository.rudn.ru/records/article/record/67553/
